Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

ion on Bioheart, visit http://www.bioheartinc.com.

Footnotes:

(1) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post-Myocardial Infarction(s)

(2) The MYOSTAR(TM) Injection Catheter is not available for sale in the U.S. It is in use in IND investigations

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson & Johnson company

Forward Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to secure additional financing; (ii) the timely success and completion of our clinical trials; (iii) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (iv) regulatory approval of our product candidates; (v) our dependence on the success of our lead product candidate; (vi) our inability to predict the extent of our future losses or if or when we will become profitable; (vii) our ability to protect our intellect
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or ... quality medical marijuana products and a licensed producer ("LP") ... Regulations ( Canada ) ("MMPR"), is pleased ... shareholders, has closed the transaction announced on March 11, ... (the "Escrow Transfer") a total of 20,156,790 common shares ...
(Date:4/24/2015)...  Blueprint Medicines today announced new preclinical data ... of fibroblast growth factor receptor 4 (FGFR4), has ... (HCC) that are dependent on FGFR4 signaling. A ... regression in a subset of mice harboring genomic ... dose levels. These data will be presented today ...
(Date:4/23/2015)... (NYSE: RMD ) today announced results for its ... was $422.5 million, a 6 percent increase compared to ... increase on a constant currency basis).  Net income was ... the quarter ended March 31, 2014.  Diluted earnings per ... 2 percent compared to the quarter ended March 31, ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
(Date:4/24/2015)... Illinois (PRWEB) April 24, 2015 Multi ... includes septic tank pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 ... to start the program. This does not include any ... applicable. Save $25-$65 per person. If someone is part ... or two tanks totaling approximately 2500 gallons or more, ...
(Date:4/24/2015)... The Fastest Fat Loss Week Ever, released ... of the Xtreme Fat Loss Diet, has been causing a ... blueprint that claims to help one lose belly fat in ... Stevenson, prompting an investigative review. , "Our Fastest Fat ... years researching and experimenting with these methods on their clients ...
(Date:4/24/2015)... April 24, 2015 The first step ... the mind. , For meditation and yoga teacher Stine ... have been invaluable tools that allow her to experience ... She has been a teacher since 2006, and through ... inner state of being. , “I love sharing this ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new ... cognition. , A unique combination of herbs and ... Flavonoid Complex apart from other antioxidant supplements. This ... support antioxidation versus the use of single or ... extract, Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with ...
(Date:4/24/2015)... 24, 2015 Insuranceautoquote.info has released a ... insurance premiums . , Lowering auto insurance prices ... to simply find better offers for their financial budget. ... it does not require any registration. , Comparing ... There are multiple agencies that sell coverage and this ...
Breaking Medicine News(10 mins):Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
... Pre-operative screening of patients for methicillin-resistant staphylococcus aureus ... rates following otolaryngic surgeries, according to new research published ... Head and Neck Surgery . , The study, ... Infirmary, is the first to review otolaryngic procedures, and ...
... decade, Equinox Fitness Clubs has been known for getting people ... Physiologist Carol Espel offers tips and advice to get even ... "The most successful results occur when our goals ... challenging piece should come in later, once new ...
... stems from presence of salicylic acid in study participants ... the key component that gives aspirin its anti-inflammatory and ... their own, a new study suggests. , Salicylic acid ... people who had not taken aspirin recently -- especially ...
... on potential antibiotic resistance , , WEDNESDAY, Dec. 31 (HealthDay ... were admitted to a hospital intensive care unit led ... study found. , The findings should settle a long-running ... preventive measure for intensive care patients offsets the risk ...
... Scientists not sure if finding points to potential problems; maker ... Women who took the osteoporosis drug Fosamax for up to ... or cells that remove old, brittle bone, a new study ... cells fused together -- with as many as 40 nuclei. ...
... VPHM ) today announced that Vincent Milano, president ... 27th Annual J.P. Morgan,Healthcare Conference at 5:30 P.M. ET ... conference is being held at the Westin St. Francis ... presentations will be webcast live for investors through, www.viropharma.com ...
Cached Medicine News:Health News:Resolve for Results: 10 Tips From Equinox Fitness Club to Help You Keep Your Resolutions in '09 2Health News:Preventive Use of Antibiotics Cuts ICU Deaths 2Health News:Osteoporosis Drug Prompts Increase in Certain Bone Cells 2Health News:Osteoporosis Drug Prompts Increase in Certain Bone Cells 3Health News:Osteoporosis Drug Prompts Increase in Certain Bone Cells 4Health News:ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference 2
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... stone manipulation and removal in the urinary tract. ... retain its shape following extreme torsion. The unique ... allowing the basket to open at the base ... tipless design reduces the likelihood of mucosal damage ...
Medicine Products: